Insider · CIK 0001296995
Jean-Pierre Sommadossi
Files at AVIR (Atea Pharmaceuticals, Inc.). First filing -, latest -.
Jean-Pierre Sommadossi files SEC Form 4 as CEO, president, chair and director at AVIR (Atea Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jean-Pierre Sommadossi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +272,983 | - | - | 573,923 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -106,093 | $4.24 | $450k | 467,830 | Feb 3, 2026 |
| Feb 3, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +300,000 | $1.24 | $372k | 767,830 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -173,466 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -99,517 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Feb 3, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +173,467 | - | - | 290,024 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Common Stock | +99,517 | - | - | 389,541 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -88,601 | $3.06 | $271k | 300,940 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -173,467 | $0.00 | $0 | 173,466 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +99,518 | $0.00 | $0 | 99,518 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Feb 4, 2025 |
Questions about Jean-Pierre Sommadossi
Answered from the filings on this page, as of the latest one.
Is Jean-Pierre Sommadossi buying or selling?
Jean-Pierre Sommadossi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jean-Pierre Sommadossi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jean-Pierre Sommadossi has 0.
Where does Jean-Pierre Sommadossi file Form 4?
Jean-Pierre Sommadossi has filed Form 4 at AVIR (Atea Pharmaceuticals, Inc.) as President, CEO, and Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.